1University of Kansas School of Medicine, 1010 N Kansas St, Wichita, KS, 67214, USA 2Cancer Center of Kansas, 818 N. Emporia #403, Wichita, KS, 67214, USA
Nathaniel A. Parker
Roles:
Conceptualization,
Methodology,
Writing – Original Draft Preparation,
Writing – Review & Editing
Ammar Al-Obaidi
Roles:
Writing – Review & Editing
Jeremy M. Deutsch
Roles:
Supervision
OPEN PEER REVIEW
REVIEWER STATUS
Abstract
The SMARCB1/INI1 gene was first discovered in the mid-1990s, and since then it has been revealed that loss of function mutations in this gene result in aggressive rhabdoid tumors. Recently, the term “rhabdoid tumor” has become synonymous with decreased SMARCB1/INI1 expression. When genetic aberrations in the SMARCB1/INI1 gene occur, the result can cause complete loss of expression, decreased expression, and mosaic expression. Although SMARCB1/INI1-deficient tumors are predominantly sarcomas, this is a diverse group of tumors with mixed phenotypes, which can often make the diagnosis challenging. Prognosis for these aggressive tumors is often poor. Moreover, refractory and relapsing progressive disease is common. As a result, accurate and timely diagnosis is imperative. Despite the SMARCB1/INI1 gene itself and its implications in tumorigenesis being discovered over two decades ago, there is a paucity of rhabdoid tumor cases reported in the literature that detail SMARCB1/INI1 expression. Much work remains if we hope to provide additional therapeutic strategies for patients with aggressive SMARCB1/INI1-deficient tumors.
Keywords
SMARCB1, INI1, loss of function mutation, rhabdoid, sarcoma
I thoroughly appreciated reviewing the comments of the Peer Reviewer. All suggestions have been addressed and the appropriate changes have been made, including minor grammatical changes and clarification of definitions. Thank you for the feedback.
I thoroughly appreciated reviewing the comments of the Peer Reviewer. All suggestions have been addressed and the appropriate changes have been made, including minor grammatical changes and clarification of definitions. Thank you for the feedback.
To read any peer review reports and author responses for this article, follow the "read" links in the Open Peer Review table.
History of the SMARCB1/INI1 Gene
SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 (SMARCB1), also known as integrase interactor 1 (INI1), is a crucial component of a chromatin-remodeling protein complex. SMARCB1/INI1 was first identified in yeast in the late 1980s1. By 1994, its human homologue was isolated in fibroblast cells2,3. Subsequent molecular investigations showed this nuclear protein complex enhances DNA transcription by interactions with HIV-1 integrase2. Nuclear SMARCB1/INI1 exists ubiquitously in all normal cells, and acts as a tumor suppressor gene4. It was revealed in the early 2000s by studies in mice that biallelic knockout of the SMARCB1/INI1 gene resulted in early lethality5. Mice with heterozygous loss before birth, or who had later conditional single-allele knockout after birth, of SMARCB1/INI1 developed aggressive rhabdoid tumors6–8. Since its discovery, much work has revealed this chromatin-remodeling protein has crucial roles in multiple signaling pathways that function to suppress tumorigenesis and tumor growth9. Although these pathways are highly complex, the development and use of targeted anti-cancer therapies has practically become ubiquitous for nearly all solid tumors. Thus, continued investigations are needed if we hope to provide additional therapeutic strategies for patients with aggressive SMARCB1/INI1-deficient tumors9.
Interestingly, the genetic signatures of SMARCB1/INI1-deficient tumors are far from monotonous. Three distinct patterns of abnormal SMARCB1/INI1 gene expression have been identified – reduced, complete loss, and mosaic9.
Epidemiology, clinical, prognosis
Complete loss of SMARCB1/INI1 expression has been linked to a number of pediatric and adult sarcomas (Table 1). Malignant rhabdoid tumor (MRT) and epithelioid sarcoma (ES) both result from biallelic deletions or mutations causing a complete loss of SMARCB1/INI1 expression41. Commonly arising before the age of three years old, MRTs are considered one of the most aggressive childhood neoplasms associated with high mortality41. MRTs have been reported in adults42–49. Based on MRT of adulthood being primarily reported anecdotally, estimated rates of incidence remain unclear. Data concerning the 5-year survival rate for MRT in adults is difficult to determine as well, as various percentages have been reported in literature13,14. However, estimated average survival following MRT diagnosis has been reported to be six months10.
Table 1. Epidemiologic, selected clinical, and prognostic data for SMARCB1/INI1-deficient tumors.
STS, soft tissue sarcomas; MRT, malignant rhabdoid tumor; CNS, central nervous system; MPNST, malignant peripheral nerve sheath tumor; NF-1, neurofibromatosis type 1; NF-2; neurofibromatosis type 2, GI, gastrointestinal; NA, data not available.
Epidemiology, Clinical
Survival
Reduced expression
Synovial sarcoma
5 – 10% of all STS; median age of 40 years; males10,11
Only 300 cases reported worldwide; median age of 50 years; males39,40
NA
ES is now categorized into two subgroups: distal and proximal. Conventional or distal-type ES tends to be histologically similar squamous cells. Also, distal-type ES immunohistochemical (IHC) profiles can be diverse. Proximal-type ES is thought to be the more aggressive variant, and has an affinity for the proximal limbs of young adults. Microscopically, sheets of large rhabdoid tumor cells are predominantly observed50. Based on more recent clinicopathologic and IHC data, many tumors that were previously diagnosed as a MRT are now classified as proximal ES51.
In addition to ES, atypical teratoid/rhabdoid tumor, renal medullary carcinoma, and pediatric chordoma are rare sarcomas that result from the complete loss of SMARCB1/INI1 expression (Table 1). They predominantly occur in pediatric or young adult patients. Collectively, these neoplasms typically develop in the head/neck, CNS, thorax, kidneys, other visceral organs, retroperitoneum, trunk, and extremities12,17,19,26,52. Exceedingly rare SMARCB1/INI1-deficient tumors that occur more commonly in adults include synovial sarcomas, epithelioid malignant peripheral nerve sheath tumor, myoepithelial carcinoma, extraskeletal myxoid chondrosarcoma, chordoma, schwannomatosis, gastrointestinal stromal tumors (GIST), and ossifying fibromyxoid tumor (Table 1). On light microscopy, these sarcomatous neoplasms exist on a morphological spectrum. Tissue specimens are often composed of epithelioid or rhabdoid cells53. However, other morphologic patterns have been described50. Thus, the diagnosis of SMARCB1/INI1-deficient tumors can be difficult based on their polyphenotypic variation4. SMARCB1/INI1 immunostaining can be used to confirm the diagnosis of an epithelioid or rhabdoid sarcoma because loss of SMARCB1/INI1 expression is rarely observed in other tumor types54,55. Thus, in the absence of this genetic alteration, other malignant soft tissue tumors with epithelioid-like morphologies can be more confidently ruled out, such as melanoma, rhabdomyosarcoma, and undifferentiated carcinoma.
Aside from SMARCB1/INI1-deficient tumors sharing an aberration in the same gene, the relationship between these malignancies remains unclear. Following diagnosis in any age or organ, nearly all SMARCB1/INI1-deficient malignancies characteristically follow an aggressive clinical pattern and prognosis is often poor (Table 1). Survival rates are often reportedly low, but they may not be accurate given low rates of incidence, and considerations for newer treatments. Also, survival can be highly dependent on surgical intervention and completeness of tumor resection, especially for chordomas. GIST are the most common sarcomas of the gastrointestinal (GI) tract. They commonly develop in the sixth decade of life and have no gender predominance35. Following the diagnosis of a GIST, survival rates are highly variable and depend on specific biologic characteristics of the tumor, the type of treatment, and the risk of post-treatment recurrence36.
Challenges in retrospective data collection for adult cases of SMARCB1/INI-deficient tumors
Recently, the term “rhabdoid tumor” has become synonymous with tumors that harbor loss of function mutations in the SMARCB1/INI1 gene56. We reviewed the literature and found a paucity of cases reporting SMARCB1/INI1 genetic aberrations in adult patients with sarcomas. A total of 450 cases of rare sarcomas were found to be described in single case reports, case series, or systematic reviews published between the years 2000 – 2020 (Table 2)57–92. This number is likely far lower than the actual accounts of reported sarcoma cases in the literature. However, reports were excluded if it was apparent the case did not meet our inclusion criteria based on the publicly-available title or abstract information. Despite the SMARCB1/INI1 gene being discovered in the mid-1990s, the majority of previous reports were excluded for not mentioning the tumor’s SMARCB1/INI1-deficiency status. Also, tumor occurrence in the pediatric patient population accounted for multiple exclusions.
Table 2. Excluded rare sarcomas in adults reported in single case reports, case series, or systematic reviews, 2000–2020.
We located 25 cases of adult SMARCB1/INI1-deficient sarcomas that were described in 18 reports (Table 3)42,50,93–108. Median age at the time of diagnosis was 36 years old. A male predominance was mildly observed (14 cases, 56%), which is consistent with other larger reviews. Presentation in the head and neck (e.g. brain, eye, nose, and scalp) occurred more frequently (6 cases, 24%). No descriptive data analysis was performed to determine if our observations were significant. The majority of reports were originally described as proximal epithelioid sarcoma, but overall these remained a morphologically diverse group of cases that also included rhabdoid and mixed phenotypes.
Table 3. Included rare sarcomas reported in single case reports, case series, or systematic reviews, 2000–2020.
Inclusion criteria were as follows: ability to confirm an individual case patient was greater than 18 years of age; documentation of a loss of SMARCB1/INI1 expression by immunohistochemistry or genetic studies; and confirmed sarcomatous histologic tumor type. “ - “ denotes complete, reduced, or mosaic loss of SMARCB1/INI1 expression (exp.). M, male; F, female.
Prior to, and still after, the discovery that SMARCB1/INI1-deficient tumors contribute to the large majority of soft tissue sarcomas, systemic cytotoxic agents have been used to treat this diverse group of neoplasms. Doxorubicin and ifosfamide have remained the mainstay of first-line treatment for advanced disease for the last few decades. Currently, the most widely used regimen for soft tissue sarcomas is termed AIM, which includes Adriamycin (doxorubicin) plus ifosfamide and mesna109–111. Therapies such as these, and other cytotoxic agents, exhibit intermediate to improved anti-cancer activity, and prolong survival in metastatic soft tissue sarcoma (Table 4). However, refractory or progressive disease can occur. With the hopes of improving outcomes in patients who develop aggressive sarcomas, multiple new therapies are being introduced. Olaratumab, a monoclonal antibody that targets platelet-derived growth factor alpha and beta (PDGFRA/B), has been approved for first-line therapy in combination with doxorubicin due to improved progression and overall survival in sarcoma patients112. The use of tyrosine kinase-inhibitors (TKIs) has transformed the treatment of advanced GIST. Imatinib, a TKI, as monotherapy is now approved for upfront treatment of metastatic GIST due to improved side effect profiles and outcomes in these patients113–115. Given its mechanism of action, imatinib is also approved for first-line treatment of the fibrosarcomatous variant of dermatofibrosarcoma protuberans116,117.
Table 4. Approved first-line treatments for sarcomas.
ORR, overall response rate; PFS, progression free survival; OS, overall survival; STS, soft tissue sarcoma; GIST, gastrointestinal stromal tumor; D, doxorubicine; I, ifosfamide; P, palifosfamide; E, Evofosfamide; T, trabectedin; O, Olaratumab; G, gemcitabine; Doc, docetaxel; NA, data not available.
Additional TKIs have recently been introduced, with clinical trial data showing promise for their use in sarcomas. Sunitinib and regorafenib significantly improve overall survival in imatinib-resistant GIST patients118. Pazopanib, a TKI that targets angiogenesis by inhibiting vascular endothelial growth factor receptor, PDGFRA/B, and KIT proto-oncogene, has been shown to improve progression free survival in certain histologic types of sarcoma. This led to its approval for advanced, refractory non-lipomatous sarcoma119,120. Alveolar sarcomas appear to respond well to anti-angiogenetic sorafenib and cediranib121,122. In phase II studies tivozanib, which mechanism of action mimics pazopanib, exhibits promising anti-cancer activity in metastatic or nonresectable soft tissue sarcomas123.
Recently, much work studying the complex mechanisms involved in sarcoma tumorigenesis has revealed the potential for numerous new drug targets. Targeting the mammalian target of rapamycin (mTOR) signaling pathway by serine/threonine kinase inhibition has been widely studied. However, thus far either only equivocal or minor benefits have been shown with the administration of these agents124. In contrast, phase II trial data is reassuring for the future use of palbociclib, a cyclin-dependent kinase 4 and 6 inhibitor approved in breast cancer, for liposarcoma125,126.
Preliminary data from pre-clinical and phase I/II trials is encouraging for small molecule inhibitors, such as with Murine double minute 2 (MDM2)–antagonists, histone deacetylase inhibitors, and histone methylation inhibitors124. A possible breakthrough in small molecular inhibition is represented by the recent discovery of a specific methyltransferase termed Enhancer of zeste homolog 2 (EZH2) is upregulated in SMARCB1/INI1-deficient tumors127. Given the defining characteristic of SMARCB1/INI1 deficiency in the nearly all soft tissue sarcomas, tazemetostat has emerged as an intriguing compound for its direct inhibition of histone-lysine N-methyltransferase EZH2127,138. Another new agent that hopes to improve outcomes for patients with these rare and aggressive SMARCB1/INI1-deficient rhabdoid sarcomas comes from the proteasome inhibitor drug class. Ixazomib selectively targets proteasomes involved in protein anabolism and cellular apoptosis, whose activity is directly enhanced by the transcription factor MYC in SMARCB1/INI1-deficient states. Currently, ixazomib plus gemcitabine and doxorubicin is being studied in the phase II trial setting for renal medullary carcinoma139,140.
Data availability
Underlying data
No data are associated with this article.
Faculty Opinions recommended
References
1.
Abrams E, Neigeborn L, Carlson M:
Molecular analysis of SNF2 and SNF5, genes required for expression of glucose-repressible genes in Saccharomyces cerevisiae.
Mol Cell Biol.
1986; 6(11): 3643–3651. PubMed Abstract
| Publisher Full Text
| Free Full Text
2.
Kalpana GV, Marmon S, Wang W, et al.:
Binding and stimulation of HIV-1 integrase by a human homolog of yeast transcription factor SNF5.
Science.
1994; 266(5193): 2002–2006. PubMed Abstract
| Publisher Full Text
3.
Muchardt C, Sardet C, Bourachot B, et al.:
A human protein with homology to Saccharomyces cerevisiae SNF5 interacts with the potential helicase hbrm.
Nucleic Acids Res.
1995; 23(7): 1127–1132. PubMed Abstract
| Publisher Full Text
| Free Full Text
4.
Hollmann TJ, Hornick JL:
INI1-deficient tumors: diagnostic features and molecular genetics.
Am J Surg Pathol.
2011; 35(10): e47–63. PubMed Abstract
| Publisher Full Text
5.
Guidi CJ, Sands AT, Zambrowicz BP, et al.:
Disruption of Ini1 leads to peri-implantation lethality and tumorigenesis in mice.
Mol Cell Biol.
2001; 21(10): 3598–3603. PubMed Abstract
| Publisher Full Text
| Free Full Text
7.
Roberts CW, Galusha SA, McMenamin ME, et al.:
Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice.
Proc Natl Acad Sci U S A.
2000; 97(25): 13796–13800. PubMed Abstract
| Publisher Full Text
| Free Full Text
8.
Roberts CW, Leroux MM, Fleming MD, et al.:
Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5.
Cancer Cell.
2002; 2(5): 415–425. PubMed Abstract
| Publisher Full Text
10.
Ferrari A, Sultan I, Huang TT, et al.:
Soft tissue sarcoma across the age spectrum: a population-based study from the Surveillance Epidemiology and End Results database.
Pediatr Blood Cancer..
2011; 57(6): 943–9. PubMed Abstract
| Publisher Full Text
| Free Full Text
11.
Rare Soft Tissue Tumors: Synovial Sarcoma. National Cancer Institute Web site. 2019. Reference Source
12.
Shonka NA, Armstrong TS, Prabhu SS, et al.:
Atypical teratoid/rhabdoid tumors in adults: a case report and treatment-focused review.
J Clin Med Res.
2011; 3(2): 85–92. PubMed Abstract
| Publisher Full Text
| Free Full Text
13.
Doyle LA:
Malignant rhabdoid tumor: Pathology of Human Disease. Academic press; 2014.
14.
Horazdovsky R, Manivel JC, Cheng EY:
Successful salvage and long-term survival after recurrent malignant rhabdoid tumor.
Sarcoma.
2007; 2007: 53549. PubMed Abstract
| Publisher Full Text
| Free Full Text
18.
Jawad MU, Extein J, Min ES, et al.:
Prognostic factors for survival in patients with epithelioid sarcoma: 441 cases from the SEER database.
Clin Orthop Relat Res.
2009; 467(11): 2939–48. PubMed Abstract
| Publisher Full Text
| Free Full Text
19.
Shetty A, Matrana MR:
Renal medullary carcinoma: a case report and brief review of the literature.
Ochsner J.
2014; 14(2): 270–5. PubMed Abstract
| Free Full Text
20.
Msaouel P:
Renal Medullary Carcinoma. National organization for Rare Disorders. 2019. Reference Source
21.
Du P, Zhu J, Zhang ZD, et al.:
Recurrent epithelioid malignant peripheral nerve sheath tumor with neurofibromatosis type 1: A case report and literature review.
Oncol Lett.
2019; 18(3): 3072–3080. PubMed Abstract
| Publisher Full Text
| Free Full Text
22.
Minagawa T, Shioya R, Sato C, et al.:
Advanced epithelioid malignant peripheral nerve sheath tumor showing complete response to combined surgery and chemotherapy: a case report.
Case Rep Oncol Med.
2011; 2011: 705345. PubMed Abstract
| Publisher Full Text
| Free Full Text
23.
Salivary Gland Cancer Treatment: Myoepithelial carcinoma. National Cancer Institute Web site, 2019. Reference Source
24.
Su YX, Roberts DB, Hanna EY, et al.:
Risk Factors and Prognosis for Myoepithelial Carcinoma of the Major Salivary Glands.
Ann Surg Oncol.
2015; 22(11): 3701–7. PubMed Abstract
| Publisher Full Text
27.
Rare Bone Tumors: Chordoma. National Cancer Institute Web site. 2019; Reference Source
28.
Smoll NR, Gautschi OP, Radovanovic I, et al.:
Incidence and relative survival of chordomas: the standardized mortality ratio and the impact of chordomas on a population.
Cancer.
2013; 119(11): 2029–37. PubMed Abstract
| Publisher Full Text
29.
Agaimy A, Haller F, Frohnauer J, et al.:
Pancreatic undifferentiated rhabdoid carcinoma: KRAS alterations and SMARCB1 expression status define two subtypes.
Mod Pathol.
2015; 28(2): 248–60. PubMed Abstract
| Publisher Full Text
30.
Agaimy A, Koch M, Lell M, et al.:
SMARCB1(INI1)-deficient sinonasal basaloid carcinoma: a novel member of the expanding family of SMARCB1-deficient neoplasms.
Am J Surg Pathol.
2014; 38(9): 1274–81. PubMed Abstract
| Publisher Full Text
| Free Full Text
33.
Romera Barba E, Sánchez Pérez A, Duque Pérez C, et al.:
Malignant rhabdoid tumor of the colon: a case report.
Cir Esp.
2014; 92(9): 638–40. PubMed Abstract
| Publisher Full Text
35.
Morgan J, Raut CP, Duensing A, et al.:
Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal stromal tumors (GIST).
UpToDate.
2019. Reference Source
36.
DeMatteo RP, Lewis JJ, Leung D, et al.:
Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.
Ann Surg.
2000; 231(1): 51–58. PubMed Abstract
| Publisher Full Text
| Free Full Text
37.
Joensuu H, Fletcher C, Dimitrijevic S, et al.:
Management of malignant gastrointestinal stromal tumours.
Lancet Oncol.
2002; 3(11): 655–664. PubMed Abstract
| Publisher Full Text
38.
Howlader N, Noone AM, Krapcho M, et al.: (eds).
SEER Cancer Statistics Review, 1975-2016. National Cancer Institute, Bethesda, MD, based on November 2018 SEER data submission, posted to the SEER website, April. 2019. Reference Source
39.
Velasco IA, Zhang R, Li T, et al.:
Ossifying Fibromyxoid tumor of soft parts in head and neck: case report and literature review.
Diagn Pathol.
2018; 13(1): 21. PubMed Abstract
| Publisher Full Text
| Free Full Text
40.
Bakiratharajan D, Rekhi B:
Ossifying Fibromyxoid Tumor: An Update.
Arch Pathol Lab Med.
2016; 140(4): 371–375. PubMed Abstract
| Publisher Full Text
41.
Pawel BR:
SMARCB1-deficient Tumors of Childhood: A Practical Guide.
Pediatr Dev Pathol.
2018; 21(1): 6–28. PubMed Abstract
| Publisher Full Text
42.
Parker NA, Al-Obaidi A, Lalich D, et al.:
SMARCB1/INI1-Deficient Extrarenal Rhabdoid Tumor: A Case Report of a Rare and Aggressive Soft Tissue Sarcoma.
Cureus.
2020; 12(5): e8273. PubMed Abstract
| Publisher Full Text
| Free Full Text
43.
Podduturi V, Campa-Thompson MM, Zhou XJ, et al.:
Malignant rhabdoid tumor of the kidney arising in an adult patient.
Proc (Bayl Univ Med Cent).
2014; 27(3): 239–41. PubMed Abstract
| Publisher Full Text
| Free Full Text
44.
Peng HQ, Stanek AE, Teichberg S, et al.:
Malignant rhabdoid tumor of the kidney in an adult: a case report and review of the literature.
Arch Pathol Lab Med.
2003; 127(9): e371–e373. PubMed Abstract
| Publisher Full Text
45.
Lowe W, Weiss RM, Todd MB, et al.:
Malignant rhabdoid tumor of the kidney in an adult.
J Urol.
1990; 143(1): 110–112. PubMed Abstract
| Publisher Full Text
46.
Clausen HV, Horn T, Anagnostaki L, et al.:
Malignant rhabdoid tumour of the kidney in an adult: a case report with immunohistochemical and ultrastructural investigation.
Scand J Urol Nephrol Suppl.
1994; 157: 123–128. PubMed Abstract
47.
Ebbinghaus SW, Herrera G, Marshall ME:
Rhabdoid tumor of the kidney in an adult: review of the literature and report of a case responding to interleukin-2.
Cancer Biother.
1995; 10(3): 237–241. PubMed Abstract
| Publisher Full Text
48.
Caballero JM, Collera P, Marti L, et al.:
[Malignant Rhabdoid Tumor of the Kidney in the Adult].
Actas Urol Esp.
1996; 20(4): 377–379. PubMed Abstract
49.
Zhao G, Na R, Yang Y, et al.:
Pure malignant rhabdoid tumor of the left kidney in an adult: A case report and review of the literature.
Oncol Lett.
2013; 5(5): 1481–1484. PubMed Abstract
| Publisher Full Text
| Free Full Text
50.
Modena P, Lualdi E, Facchinetti F, et al.:
SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas.
Cancer Res.
2005; 65(10): 4012–9. PubMed Abstract
| Publisher Full Text
51.
Margol AS, Judkins AR:
Pathology and diagnosis of SMARCB1-deficient tumors.
Cancer Genet.
2014; 207(9): 358–64. PubMed Abstract
| Publisher Full Text
53.
Gupta RK, Batra VV, Das MC, et al.:
Malignant extra-renal rhabdoid tumor with unusual presentation: A report of two cases.
J Cancer Res Ther.
2015; 11(4): 963–6. PubMed Abstract
| Publisher Full Text
54.
Hoot AC, Russo P, Judkins AR, et al.:
Immunohistochemical analysis of hSNF5/INI1 distinguishes renal and extra-renal malignant rhabdoid tumors from other pediatric soft tissue tumors.
Am J Surg Pathol..
2004; 28(11): 1485–91. PubMed Abstract
| Publisher Full Text
55.
Chbani L, Guillou L, Terrier P, et al.:
Epithelioid sarcoma: a clinicopathologic and immunohistochemical analysis of 106 cases from the French sarcoma group.
Am J Clin Pathol.
2009; 131(2): 222–227. PubMed Abstract
| Publisher Full Text
56.
Kohashi K, Tanaka Y, Kishimoto H, et al.:
Reclassification of rhabdoid tumor and pediatric undifferentiated/unclassified sarcoma with complete loss of SMARCB1/INI1 protein expression: three subtypes of rhabdoid tumor according to their histological features.
Mod Pathol.
2016; 29(10): 1232–1242. PubMed Abstract
| Publisher Full Text
57.
Zhang XW, Deng YJ, Zhou L, et al.:
Epithelioid sarcoma of the scalp: a case report and literature review.
Int J Clin Exp Pathol.
2019; 12(10): 3908–3914. PubMed Abstract
| Free Full Text
58.
Kubota Y, Arakawa Y, Sekiguchi M, et al.:
A case of malignant rhabdoid tumor mimicking yolk sac tumor.
Pediatr Blood Cancer.
2019; 66(8): e27784. PubMed Abstract
| Publisher Full Text
59.
Kolin DL, Dong F, Baltay M, et al.:
SMARCA4-deficient undifferentiated uterine sarcoma (malignant rhabdoid tumor of the uterus): a clinicopathologic entity distinct from undifferentiated carcinoma.
Mod Pathol.
2018; 31(9): 1442–1456. PubMed Abstract
| Publisher Full Text
60.
Kim YS, Kwak HS, Chung GH, et al.:
Epithelioid sarcoma arising from the temporal space: A case report.
Medicine (Baltimore).
2018; 97(38): e12529. PubMed Abstract
| Publisher Full Text
| Free Full Text
61.
Strehl JD, Wachter DL, Fiedler J, et al.:
Pattern of SMARCB1 (INI1) and SMARCA4 (BRG1) in poorly differentiated endometrioid adenocarcinoma of the uterus: analysis of a series with emphasis on a novel SMARCA4-deficient dedifferentiated rhabdoid variant.
Ann Diagn Pathol.
2015; 19(4): 198–202. PubMed Abstract
| Publisher Full Text
63.
Patrizi L, Corrado G, Saltari M, et al.:
Vulvar "proximal-type" epithelioid sarcoma: report of a case and review of the literature.
Diagn Pathol.
2013; 8: 122. PubMed Abstract
| Publisher Full Text
| Free Full Text
64.
Tocco I, Bassetto F, Vindigni V:
Primary epithelioid sarcoma of the scalp complicated by humoral hypercalcemia of malignancy.
Eplasty.
2012; 12: ic18. PubMed Abstract
| Free Full Text
65.
Rizzo D, Fréneaux P, Brisse H, et al.:
SMARCB1 deficiency in tumors from the peripheral nervous system: a link between schwannomas and rhabdoid tumors?
Am J Surg Pathol.
2012; 36(7): 964–72. PubMed Abstract
| Publisher Full Text
66.
Kuge A, Sato S, Sakurada K, et al.:
Atypical teratoid rhabdoid tumor located in the pineal region following prophylactic irradiation for acute lymphoblastic leukemia.
Brain Tumor Pathol.
2012; 29(3): 177–81. PubMed Abstract
| Publisher Full Text
67.
Hagström J, Mesimäki K, Apajalahti S, et al.:
A rare case of oral epithelioid sarcoma of the gingiva.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod.
2011; 111(4): e25–8. PubMed Abstract
| Publisher Full Text
68.
Narendra H, Ray S, Rao L, et al.:
Malignant extrarenal rhabdoid tumor of the vulva in an adult.
J Cancer Res Ther.
2010; 6(1): 82–5. PubMed Abstract
| Publisher Full Text
69.
Tholpady A, Lonergan CL, Wick MR:
Proximal-type epithelioid sarcoma of the vulva: relationship to malignant extrarenal rhabdoid tumor.
Int J Gynecol Pathol.
2010; 29(6): 600–4. PubMed Abstract
| Publisher Full Text
70.
Hornick JL, Dal Cin P, Fletcher CDM:
Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma.
Am J Surg Pathol.
2009; 33(4): 542–50. PubMed Abstract
| Publisher Full Text
72.
Rekhi B, Gorad BD, Chinoy RF:
Clinicopathological features with outcomes of a series of conventional and proximal-type epithelioid sarcomas, diagnosed over a period of 10 years at a tertiary cancer hospital in India.
Virchows Arch.
2008; 453(2): 141–153. PubMed Abstract
| Publisher Full Text
73.
Argenta PA, Thomas S, Chura JC:
Proximal-type epithelioid sarcoma vs. malignant rhabdoid tumor of the vulva: a case report, review of the literature, and an argument for consolidation.
Gynecol Oncol.
2007; 107(1): 130–135. PubMed Abstract
| Publisher Full Text
74.
Bourdeaut F, Fréneaux P, Thuille B, et al.:
hSNF5/INI1-deficient tumours and rhabdoid tumours are convergent but not fully overlapping entities.
J Pathol.
2007; 211(3): 323–330. PubMed Abstract
| Publisher Full Text
76.
Onol FF, Tanidir Y, Kotiloğlu E, et al.:
Proximal type epithelioid sarcoma of the scrotum: a source of diagnostic confusion that needs immediate attention.
Eur Urol.
2006; 49(2): 406–407. PubMed Abstract
| Publisher Full Text
77.
Zevallos-Giampietri EA, Barrionuevo C:
Proximal-type epithelioid sarcoma: report of two cases in the perineum: differential diagnosis and review of soft tissue tumors with epithelioid and/or rhabdoid features.
Appl Immunohistochem Mol Morphol.
2005; 13(3): 221–230. PubMed Abstract
| Publisher Full Text
78.
Masunaga A, Ikeda K, Suzuki T, et al.:
Proximal-type epithelioid sarcoma in a 36-year-old man: closer immunoelectron-microscopic resemblance of the tumor cells to epithelial cells than to mesenchymal cells.
Pathol Int.
2004; 54(8): 616–622. PubMed Abstract
| Publisher Full Text
79.
Chang JH, Dikranian AH, Johnston WH, et al.:
Malignant extrarenal rhabdoid tumor of the bladder: 9-year survival after chemotherapy and partial cystectomy.
J Urol.
2004; 171(2 Pt 1): 820–821. PubMed Abstract
| Publisher Full Text
80.
Altundag K, Dikbas O, Oyan B, et al.:
Epithelioid sarcoma of vulva: a case report and review of the literature.
Med Oncol.
2004; 21(4): 367–372. PubMed Abstract
| Publisher Full Text
81.
Lee MW, Jee KJ, Ro JY, et al.:
Proximal-type epithelioid sarcoma: case report and result of comparative genomic hybridization.
J Cutan Pathol.
2004; 31(1): 67–71. PubMed Abstract
| Publisher Full Text
82.
Hanna SL, Kaste S, Jenkins JJ, et al.:
Epithelioid sarcoma: clinical, MR imaging and pathologic findings.
Skeletal Radiol.
2002; 31(7): 400–412. PubMed Abstract
| Publisher Full Text
83.
Etienne-Mastroianni B, Falchero L, Chalabreysse L, et al.:
Primary sarcomas of the lung: a clinicopathologic study of 12 cases.
Lung Cancer.
2002; 38(3): 283–289. PubMed Abstract
| Publisher Full Text
84.
Moore RG, Steinhoff MM, Granai CO, et al.:
Vulvar epithelioid sarcoma in pregnancy.
Gynecol Oncol.
2002; 85(1): 218–222. PubMed Abstract
| Publisher Full Text
85.
Haidopoulos D, Elsheikh A, Vlahos G, et al.:
Malignant rhabdoid tumor of the clitoris in an elderly patient: report of a case.
Eur J Gynaecol Oncol.
2002; 23(5): 447–449. PubMed Abstract
86.
Tzilinis A, Clarke LE, Affuso C, et al.:
Successful treatment of malignant rhabdoid tumor of the vulva in an older patient: a case report and review of the literature.
Curr Surg.
2002; 59(6): 570–571. PubMed Abstract
| Publisher Full Text
87.
Amrikachi M, Ro JY, Ordonez NG, et al.:
Adenocarcinomas of the gastrointestinal tract with prominent rhabdoid features.
Ann Diagn Pathol.
2002; 6(6): 357–363. PubMed Abstract
| Publisher Full Text
88.
Hasegawa T, Matsuno Y, Shimoda T, et al.:
Proximal-type epithelioid sarcoma: a clinicopathologic study of 20 cases.
Mod Pathol.
2001; 14(7): 655–663. PubMed Abstract
| Publisher Full Text
89.
Kasamatsu T, Hasegawa T, Tsuda H, et al.:
Primary epithelioid sarcoma of the vulva.
Int J Gynecol Cancer.
2001; 11(4): 316–320. PubMed Abstract
| Publisher Full Text
90.
Knapik J, Yachnis AT, Ripley D, et al.:
Aggressive uterine sarcoma with rhabdoid features: diagnosis by peritoneal fluid cytology and absence of INI1 gene mutation.
Hum Pathol.
2001; 32(8): 884–886. PubMed Abstract
| Publisher Full Text
91.
Biegel JA, Fogelgren B, Wainwright LM, et al.:
Germline INI1 mutation in a patient with a central nervous system atypical teratoid tumor and renal rhabdoid tumor.
Genes Chromosomes Cancer.
2000; 28(1): 31–37. PubMed Abstract
| Publisher Full Text
92.
Spillane AJ, Thomas JM, Fisher C:
Epithelioid sarcoma: the clinicopathological complexities of this rare soft tissue sarcoma.
Ann Surg Oncol.
2000; 7(3): 218–225. PubMed Abstract
| Publisher Full Text
93.
Ahmad Z, Stanazai Q, Wright S, et al.:
Primary pleural epithelioid sarcoma of the proximal type: a diagnostic and therapeutic challenge.
Transl Lung Cancer Res.
2019; 8(5): 700–705. PubMed Abstract
| Publisher Full Text
| Free Full Text
94.
Bodi I, Giamouriadis A, Sibtain N, et al.:
Primary intracerebral INI1-deficient rhabdoid tumor with CD34 immunopositivity in a young adult.
Surg Neurol Int.
2018; 9: 45. PubMed Abstract
| Publisher Full Text
| Free Full Text
95.
Gurwale S, Gore C, Kaur S, et al.:
Primary epithelioid sarcoma of scalp.
Asian J Oncol.
2017; 3: 71–73. Publisher Full Text
96.
Saha D, Basu A, Maiti A, et al.:
Primary proximal epithelioid sarcoma of the lung successfully treated with pneumonectomy and adjuvant chemotherapy.
BMJ Case Rep.
2016; 2016: bcr2015213966. PubMed Abstract
| Publisher Full Text
| Free Full Text
98.
Wetzel SL, Kerpel S, Reich RF, et al.:
Malignant rhabdoid tumor of the floor of mouth: first reported case in the oral cavity of an adult.
Head Neck Pathol.
2015; 9(2): 269–272. PubMed Abstract
| Publisher Full Text
| Free Full Text
99.
Agaimy A, Rau TT, Hartmann A, et al.:
SMARCB1 (INI1)-negative rhabdoid carcinomas of the gastrointestinal tract: clinicopathologic and molecular study of a highly aggressive variant with literature review.
Am J Surg Pathol.
2014; 38(7): 910–920. PubMed Abstract
| Publisher Full Text
100.
Madsen GA, Rasmussen TR, Bærentzen S:
A case of pleural epithelioid sarcoma of proximal type presenting as malignant pleural mesothelioma.
J Thorac Oncol.
2013; 8(10): e89–e90. PubMed Abstract
| Publisher Full Text
101.
Frank R, Sadri N, Bhatti T, et al.:
Proximal-type Epithelioid Sarcoma of the Head and Neck (HN): A Study with Immunohistochemical and Molecular Analysis of SMARCB1.
J Clin Exp Oncol.
2013; 2(2): 1000106. PubMed Abstract
| Publisher Full Text
| Free Full Text
102.
Kim HJ, Kim MH, Kwon J, et al.:
Proximal-type epithelioid sarcoma of the vulva with INI1 diagnostic utility.
Ann Diagn Pathol.
2012; 16(5): 411–415. PubMed Abstract
| Publisher Full Text
103.
Mannan AA, Rifaat AA, Kahvic M, et al.:
Proximal-type epithelioid sarcoma in the groin presenting as a diagnostic dilemma.
Pathol Oncol Res.
2010; 16(2): 181–188. PubMed Abstract
| Publisher Full Text
104.
Takei H, Adesina AM, Mehta V, et al.:
Atypical teratoid/rhabdoid tumor of the pineal region in an adult.
J Neurosurg.
2010; 113(2): 374–379. PubMed Abstract
| Publisher Full Text
105.
Raoux D, Péoc'h M, Pedeutour F, et al.:
Primary epithelioid sarcoma of bone: report of a unique case, with immunohistochemical and fluorescent in situ hybridization confirmation of INI1 deletion.
Am J Surg Pathol.
2009; 33(6): 954–958. PubMed Abstract
| Publisher Full Text
106.
Robbens C, Vanwyck R, Wilms G, et al.:
An extrarenal rhabdoid tumor of the cervical spine with bony involvement.
Skeletal Radiol.
2007; 36(4): 341–345. PubMed Abstract
| Publisher Full Text
107.
Sigauke E, Rakheja D, Maddox DL, et al.:
Absence of expression of SMARCB1/INI1 in malignant rhabdoid tumors of the central nervous system, kidneys and soft tissue: an immunohistochemical study with implications for diagnosis.
Mod Pathol.
2006; 19(5): 717–725. PubMed Abstract
| Publisher Full Text
108.
Perry A, Fuller CE, Judkins AR, et al.:
INI1 expression is retained in composite rhabdoid tumors, including rhabdoid meningiomas.
Mod Pathol.
2005; 18(7): 951–958. PubMed Abstract
| Publisher Full Text
109.
Edmonson JH, Ryan LM, Blum RH, et al.:
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
J Clin Oncol.
1993; 11(7): 1269–75. PubMed Abstract
| Publisher Full Text
110.
Cesne A, Judson I, Crowther D, et al.:
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group.
J Clin Oncol.
2000; 18(14): 2676–84. PubMed Abstract
| Publisher Full Text
111.
Worden FP, Taylor JM, Biermann JS, et al.:
Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma.
J Clin Oncol.
2005; 23(1): 105–12. PubMed Abstract
| Publisher Full Text
112.
Tap WD, Jones RL, Van Tine BA, et al.:
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. [published correction appears in Lancet. 2016 Jul 30; 388(10043):464].
Lancet.
2016; 388(10043): 488–497. PubMed Abstract
| Publisher Full Text
| Free Full Text
113.
van Oosterom AT, Judson I, Verweij J, et al.:
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.
Lancet.
2001; 358(9291): 1421–1423. PubMed Abstract
| Publisher Full Text
114.
Demetri GD, von Mehren M, Blanke CD, et al.:
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
N Engl J Med.
2002; 347(7): 472–480. PubMed Abstract
| Publisher Full Text
115.
Blanke CD, Rankin C, Demetri GD, et al.:
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
J Clin Oncol.
2008; 26(4): 626–632. PubMed Abstract
| Publisher Full Text
116.
Rutkowski P, Van Glabbeke M, Rankin CJ, et al.:
Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials.
J Clin Oncol.
2010; 28(10): 1772–1779. PubMed Abstract
| Publisher Full Text
| Free Full Text
117.
Stacchiotti S, Pantaleo MA, Negri T, et al.:
Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP).
Clin Cancer Res.
2016; 22(4): 837–846. PubMed Abstract
| Publisher Full Text
118.
Call JW, Wang Y, Montoya D, et al.:
Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry. [published correction appears in Clin Sarcoma Res. 2019 May 7;9:7].
Clin Sarcoma Res.
2019; 9: 4. PubMed Abstract
| Publisher Full Text
| Free Full Text
119.
van der Graaf WTA, Blay JY, Chawla SP, et al.:
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.
Lancet.
2012; 379(9829): 1879–86. PubMed Abstract
| Publisher Full Text
120.
Sleijfer S, Ray-Coquard I, Papai Z, et al.:
Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).
J Clin Oncol.
2009; 27(19): 3126–32. PubMed Abstract
| Publisher Full Text
121.
Ray-Coquard I, Italiano A, Bompas E, et al.:
Sorafenib for Patients With Advanced Angiosarcoma: A Phase II Trial From the French Sarcoma Group (GSF/GETO).
Oncologist.
2012; 17(2): 260–266. PubMed Abstract
| Publisher Full Text
| Free Full Text
123.
Agulnik M, Costa RLB, Milhem M, et al.:
A Phase II Study of Tivozanib in Patients With Metastatic and Nonresectable Soft-Tissue Sarcomas.
Ann Oncol.
2017; 28(1): 121–127. PubMed Abstract
| Publisher Full Text
| Free Full Text
124.
Frezza AM, Stacchiotti S, Gronchi A:
Systemic Treatment in Advanced Soft Tissue Sarcoma: What Is Standard, What Is New.
BMC Med.
2017; 15(1): 109. PubMed Abstract
| Publisher Full Text
| Free Full Text
125.
Binh MB, Sastre-Garau X, Guillou L, et al.:
MDM2 and CDK4 Immunostainings Are Useful Adjuncts in Diagnosing Well-Differentiated and Dedifferentiated Liposarcoma Subtypes: A Comparative Analysis of 559 Soft Tissue Neoplasms With Genetic Data.
Am J Surg Pathol.
2005; 29(10): 1340–1347. PubMed Abstract
| Publisher Full Text
126.
Dickson MA, Tap WD, Keohan ML, et al.:
Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.
J Clin Oncol.
2013; 31(16): 2024–8. PubMed Abstract
| Publisher Full Text
| Free Full Text
127.
Wilson BG, Wang X, Shen X, et al.:
Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. [published correction appears in Cancer Cell. 2011 Jan 18; 19(1): 153]
Cancer Cell.
2010; 18(4): 316–28. PubMed Abstract
| Publisher Full Text
| Free Full Text
128.
Judson I, Verweij J, Gelderblom H, et al.:
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Lancet Oncol.
2014; 15(4): 415–423. PubMed Abstract
| Publisher Full Text
129.
Ryan CW, Merimsky O, Agulnik M, et al.:
PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma.
J Clin Oncol.
2016; 34(32): 3898–3905. PubMed Abstract
| Publisher Full Text
130.
Tap WD, Papai Z, Van Tine BA, et al.:
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial.
Lancet Oncol.
2017; 18(8): 1089–1103, [published correction appears in Lancet Oncol. 2018 Feb; 19(2):e78]. PubMed Abstract
| Publisher Full Text
131.
Martin-Broto J, Pousa AL, de Las Peñas R, et al.:
Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study.
J Clin Oncol.
2016; 34(19): 2294–2302. PubMed Abstract
| Publisher Full Text
132.
Bui-Nguyen B, Butrynski JE, Penel N, et al.:
A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: the TRUSTS trial.
Eur J Cancer.
2015; 51(10): 1312–1320. PubMed Abstract
| Publisher Full Text
133.
Chawla SP, Papai Z, Mukhametshina G, et al.:
First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial.
JAMA Oncol.
2015; 1(9): 1272–1280. PubMed Abstract
| Publisher Full Text
134.
Gupta S, Gouw L, Wright J, et al.:
Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation.
Invest New Drugs.
2016; 34(2): 243–252. PubMed Abstract
| Publisher Full Text
135.
Seddon B, Strauss SJ, Whelan J, et al.:
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
Lancet Oncol.
2017; 18(10): 1397–1410. PubMed Abstract
| Publisher Full Text
| Free Full Text
136.
Gelderblom H, Blay JY, Seddon BM, et al.:
Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study.
Eur J Cancer.
2014; 50(2): 388–96. PubMed Abstract
| Publisher Full Text
137.
Penel N, Bui BN, Bay JO, et al.:
Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.
J Clin Oncol.
2008; 26(32): 5269–74. PubMed Abstract
| Publisher Full Text
138.
Agulnik M, Tannir NM, Pressey JG, et al.:
A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adult subjects with INI1-negative tumors or relapsed/refractory synovial sarcoma.
J Clin Oncol.
2016; 34(15_suppl): TPS11071–TPS11071. (suppl; abstr TPS11071). Publisher Full Text
139.
Msaouel P, Carugo A, Genovese G:
Targeting proteostasis and autophagy in SMARCB1-deficient malignancies: where next?
Oncotarget.
2019; 10(40): 3979–3981. PubMed Abstract
| Publisher Full Text
| Free Full Text
140.
Msaouel P, Slack-Tidwell R, Genovese G, et al.:
Phase II trial of ixazomib combined with gemcitabine and doxorubicin in patients with SMARCB1-deficient kidney malignancies.
J Clin Oncol.
2019; 37(7_suppl): (suppl; abstr TPS678–TPS678). Publisher Full Text
1
University of Kansas School of Medicine, 1010 N Kansas St, Wichita, KS, 67214, USA 2
Cancer Center of Kansas, 818 N. Emporia #403, Wichita, KS, 67214, USA
Nathaniel A. Parker
Roles:
Conceptualization,
Methodology,
Writing – Original Draft Preparation,
Writing – Review & Editing
Parker NA, Al-Obaidi A and Deutsch JM. SMARCB1/INI1-deficient tumors of adulthood [version 2; peer review: 2 approved]. F1000Research 2020, 9:662 (https://doi.org/10.12688/f1000research.24808.2)
NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.
Share
Open Peer Review
Current Reviewer Status:
?
Key to Reviewer Statuses
VIEWHIDE
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations
A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
This is a review article highlighting the recently published case reports on the role of SMARCB1/INI1-deficient tumors of adulthood and available treatment strategies.
This review summarized important findings and is theoretically based on the current literature.
... Continue reading
This is a review article highlighting the recently published case reports on the role of SMARCB1/INI1-deficient tumors of adulthood and available treatment strategies.
This review summarized important findings and is theoretically based on the current literature.
The subject is very important to basic oncology practice.
The paper is well-written and provides useful information for the readers.
Is the topic of the review discussed comprehensively in the context of the current literature?
Yes
Are all factual statements correct and adequately supported by citations?
Yes
Is the review written in accessible language?
Yes
Are the conclusions drawn appropriate in the context of the current research literature?
Yes
Competing Interests: No competing interests were disclosed.
I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
This article clearly and concisely reviews the role of SMARCB1/INI1 in rhabdoid tumours, as well as summarising the literature and discussing management options. The structure is good, the language is accessible, and the references are appropriate and comprehensive.
I
... Continue reading
This article clearly and concisely reviews the role of SMARCB1/INI1 in rhabdoid tumours, as well as summarising the literature and discussing management options. The structure is good, the language is accessible, and the references are appropriate and comprehensive.
I would suggest a short conclusion to recap the main points and to ensure that there are clear learning outcomes for readers of varying experience levels.
Below are minor grammar/punctuation corrections and suggestions:
"the result can cause reduced, complete loss, and mosaic expression." - this is not clear - I would suggest changing to "the result can cause reduced expression, complete loss of expression, and mosaic expression" ?
There should be no apostrophe in 1980’s or 2000's, i.e. 1980s and 2000s are correct.
In Table 1 "typically presents in intraabdominally in adult males" the first "in" is an error.
"CNS" is used without expansion/explanation of the acronym.
"prognosis if often poor" - should read "is often poor".
In Tables 2 and 3 "criteria was as follows" should be "were as follows".
"A male predominance was mildly observed (14 cases, 56%), which is consistent with other larger reviews." - this wording is unclear - suggest "Consistent with other larger reviews, there was a slight male predominance (14 cases, 56%)."
"is termed AIM, which includes doxorubicin plus ifosfamide and mesna" - explain this more clearly so that the initialism (AIM) makes sense.
"KIT" is not an acronym/initialism but suggest "KIT proto-oncogene" so that it is clear what it is.
Explain what "mTOR" and "MDM2" and "EZH2" stand for.
"as a highly intriguing" - remove the word "highly".
Is the topic of the review discussed comprehensively in the context of the current literature?
Yes
Are all factual statements correct and adequately supported by citations?
Yes
Is the review written in accessible language?
Yes
Are the conclusions drawn appropriate in the context of the current research literature?
Yes
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Orbital rhabdomyosarcoma.
I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations -
A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Adjust parameters to alter display
View on desktop for interactive features
Includes Interactive Elements
View on desktop for interactive features
Competing Interests Policy
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Examples of 'Non-Financial Competing Interests'
Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.
You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.
You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).
You work at the same institute as any of the authors.
You hope/expect to benefit (e.g. favour or employment) as a result of your submission.
You are an Editor for the journal in which the article is published.
Examples of 'Financial Competing Interests'
You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.
You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.
You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.
Stay Updated
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Comments on this article Comments (0)